| Literature DB >> 24717798 |
Peter S Lee1, Nobuko Ohshima2, Robyn L Stanfield3, Wenli Yu3, Yoshitaka Iba2, Yoshinobu Okuno4, Yoshikazu Kurosawa2, Ian A Wilson1.
Abstract
Influenza viruses present a significant health challenge each year, as in the H3N2 epidemic of 2012-2013. Here we describe an antibody, F045-092, that possesses broadly neutralizing activity against the entire H3 subtype and accommodates the natural variation and additional glycosylation in all strains tested from 1963 to 2011. Crystal structures of F045-092 in complex with HAs from 1975 and 2011 H3N2 viruses reveal the structural basis for its neutralization breadth through insertion of its 23-residue HCDR3 into the receptor-binding site that involves striking receptor mimicry. F045-092 extends its recognition to divergent subtypes, including H1, H2 and H13, using the enhanced avidity of its IgG to overcome lower-affinity Fab binding, as observed with other antibodies that target the receptor-binding site. This unprecedented level of antibody cross-reactivity against the H3 subtype can potentially inform on development of a pan-H3 vaccine or small-molecule therapeutics.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24717798 PMCID: PMC4358779 DOI: 10.1038/ncomms4614
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919